Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aminolevulinic acid
- Development stage
- Approved
- Lead developer
- Biofrontera
- Modality
- Small Molecules
- Administration
- Topical, Oral, Intraperitoneal
01
Overview
Aminolevulinic acid (ALA) is a naturally occurring metabolic precursor of heme that is converted intracellularly into the potent photosensitizer protoporphyrin IX (PpIX). When administered either topically or systemically, ALA preferentially accumulates in rapidly proliferating cells, such as tumor cells or psoriatic plaques. Upon activation by specific wavelengths of light (photodynamic therapy, PDT) or ultrasound (sonodynamic therapy, SDT), PpIX generates reactive oxygen species, primarily singlet oxygen, which induce selective tissue necrosis or apoptosis. Additionally, the fluorescence of PpIX under blue light allows for photodynamic diagnosis (PDD) and intraoperative visualization of malignant tissues. ALA is FDA-approved for the treatment of actinic keratosis and for the visualization of malignant gliomas during surgery, and it is being investigated for various other oncological and dermatological indications.
- Brand names
- AmeluzGliolanLevulanLevulan KerastickAlaceic
- Other names
- 5-aminolevulinic aciddelta-aminolevulinic acid5-aminolevulinic acid hydrochlorideALA HCl
02
Targets
ALAD (5-aminolevulinic acid dehydratase)
Beyond the preview
Go deeper on aminolevulinic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aminolevulinic acid.